Why hip cartilage cannot repair itself

The short answer is no. Hip cartilage does not grow back on its own, and that is not a matter of clinical caution — it is basic biology.

The articular surface of the hip joint is lined with hyaline cartilage, a dense, glassy tissue that absorbs load and allows the ball and socket to move smoothly. Hyaline cartilage contains no blood vessels and no nerves. Two independent 2024 engineering reviews confirm that this avascular nature is the primary barrier to spontaneous repair: without a blood supply, the progenitor cells that normally respond to tissue injury simply cannot reach the damaged area. Cartilage that wears away or tears does not trigger the healing cascade that mends bone or muscle. The defect persists — and, if left untreated, may enlarge and accelerate joint degeneration.

Understanding this early is genuinely useful, because it reframes the question. The aim of treatment is not to regrow lost tissue from scratch; it is to support the body's own limited repair capacity, slow further loss, and relieve pain. The sections that follow explain the injectable and, where relevant, surgical options available for hip cartilage damage — including what each can and cannot achieve.

What 'Liquid Cartilage' actually means

'Liquid Cartilage' is a colloquial marketing label, not a description of what is inside the syringe. Patients who encounter the term online sometimes assume cartilage cells — or something equivalent — are being injected directly into the joint. Neither is the case.

The product behind the name is ChondroFiller®, a registered trademark of Meidrix Biomedicals GmbH. It is a CE-marked Class III medical device: an injectable, collagen-based scaffold that gels in situ once placed at the site of a focal cartilage defect. It contains no live chondrocytes and no cartilage tissue. What it provides is a structured microenvironment — a collagen matrix — that coats the damaged load-bearing surface and creates conditions that may support the body's own repair processes.

The clinical mechanism is described as acellular matrix-induced chondrogenesis. In plain terms: the scaffold recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, giving them a physical framework within which focal repair can occur. The body does the biological work; the scaffold provides the architecture.

This scaffold-versus-regeneration distinction matters clinically. ChondroFiller is not a substitute for lost cartilage, and it does not replace the tissue that was there before. It is more accurately understood as repair support — promoting endogenous repair rather than delivering new cartilage from an external source. Patients considering the treatment benefit from understanding this before deciding whether it fits their situation.

How a ChondroFiller injection works in the hip joint

The injection itself takes place under real-time ultrasound guidance at an outpatient appointment — no general anaesthetic, no surgical incision, no theatre admission. A fine needle is directed to the focal cartilage defect inside the hip joint, and the collagen-based scaffold is deposited directly at the site. Image guidance allows the clinician to confirm accurate placement before withdrawing the needle; patients leave the same day.

Once in position, the collagen matrix gels in situ and adheres to the exposed surfaces at the defect margin. From that point, the biological process unfolds gradually. Progenitor cells — drawn from the surrounding synovium and from the subchondral bone immediately beneath the defect — migrate into the scaffold's porous architecture. Think of the collagen framework as scaffolding on a building site: the structure itself does no building, but it gives the body's own cells somewhere to work. Over the following months, those migrating cells deposit new matrix within the defect, producing fibrocartilaginous repair tissue.

That tissue is not identical to native hyaline cartilage — fibrocartilage is biomechanically softer — but it occupies and stabilises the defect rather than leaving exposed bone beneath the joint. Published hip series have recorded improvements in pain and function scores, suggesting the repair tissue can achieve meaningful functional benefit even without a perfect biological restoration.

The time horizon is important for realistic expectations. Scaffold remodelling is slow; most patients do not experience the full effect within the first few weeks, and the tissue continues to consolidate over several months. A six-week review is built into the pathway to assess early progress. Professor Paul Y.F. Lee, who introduced ChondroFiller to the UK as an injectable pathway, now delivers it under ultrasound guidance for suitable focal hip defects. Larger defects may require two or three boxes of product, with eligibility determined by defect stage and joint condition rather than age alone.

Who is a suitable candidate for a hip ChondroFiller injection

Not every hip patient is a candidate for ChondroFiller, and understanding where the treatment fits — and where it does not — is the most useful starting point before any consultation.

ChondroFiller is designed for focal cartilage defects: discrete areas of damage in an otherwise structurally reasonable hip joint. Patients with early-to-moderate cartilage loss — the kind associated with femoroacetabular impingement (FAI), a discrete injury, or early wear — are typically the ones assessed for this injection pathway. The scaffold creates a microenvironment for the body's own progenitor cells to work; where cartilage loss is diffuse and bone is already exposed across a wide area, there is insufficient tissue context for that repair to take hold.

End-stage hip osteoarthritis — widespread cartilage loss with severely narrowed joint space — falls outside the indication. In those circumstances, a conversation about hip replacement is generally more appropriate.

There is no stated upper age limit and no defect-size cut-off for eligibility. Suitability turns on defect character and joint condition rather than age or dimensions alone. Patients are typically assessed with imaging to characterise defect depth, location, and stage before any treatment decision is reached.

For those uncertain where they sit on that spectrum, the assessment itself provides the answer. Lincolnshire Hip accepts patients without a GP referral, and an initial appointment in Grantham or Sleaford establishes whether ChondroFiller, another injection pathway, or a different route fits the clinical picture.

What the evidence says about outcomes

Early clinical data from hip-specific series suggests that ChondroFiller can produce meaningful improvements in joint function and pain. Published results record an improvement of approximately 30 points in the modified Harris Hip Score (mHHS) — a validated 100-point measure of hip pain, walking ability, and daily activities. In practical terms, a 30-point gain is the kind of shift that can move a patient from struggling with a short walk or getting in and out of a car, to managing stairs and low-impact activity with considerably less discomfort. That is a tangible functional change, not a marginal one.

The evidence base behind that figure needs to be read clearly: the results come from case-series and observational data rather than randomised controlled trials. No RCT comparing ChondroFiller against a control group in the hip joint has been published. This places the treatment at an early-promising tier — the data is encouraging, but it is not yet at the level of guideline endorsement, and outcomes should be understood as directional rather than uniform.

The 2021 Orthoregeneration Network hip review, which assessed injectable biologics for hip chondral lesions, frames this honestly: the primary goals of scaffold-based and biologic injection pathways are pain relief, support for the body's own repair processes, and delay of progression towards joint replacement. For a patient with a focal hip defect who is not yet at the stage of requiring surgery, those goals can represent a significant improvement in quality of life — particularly when the alternative is waiting for the joint to deteriorate further.

Other hip injection options at Lincolnshire Hip

Three injections, three mechanisms — and the distinctions matter clinically, not just commercially.

ChondroFiller (guide cost £2,995 at Lincolnshire Hip) is the scaffold option: a collagen matrix placed under ultrasound guidance that recruits the body's own progenitor cells into a focal defect. Arthrosamid (£2,995) works through an entirely different route — a polyacrylamide hydrogel that integrates into the synovial lining and acts as a long-lasting mechanical cushion for an osteoarthritic joint. There is no regenerative mechanism; it addresses joint loading and pain rather than defect repair, and is not interchangeable with ChondroFiller despite sharing a price point.

PRP (£1,200) is regenerative-leaning, using concentrated growth factors from the patient's own blood to support the healing environment around damaged tissue — applicable across a range of severity, though the evidence base is stronger in earlier-stage disease. Hyaluronic acid viscosupplementation, a fourth pathway, mimics depleted synovial fluid to reduce friction and ease arthritic pain; it is palliative rather than regenerative, and clinical guidelines differ on how meaningful its specific benefit is in the hip joint.

None of these approaches — ChondroFiller included — restores true hyaline cartilage. All are best understood as symptom management and repair support at different positions along the joint-preservation spectrum. The choice between them turns on defect character, disease stage, and what the hip actually needs — factors that clinical assessment establishes rather than any price comparison. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment at its Grantham and Sleaford clinics.

1. [1] Hydrogel-Based 3D Bioprinting Technology for Articular Cartilage Regenerative Engineering. (2024). https://doi.org/10.3390/gels10070430 https://doi.org/10.3390/gels10070430
2. [2] Biomimetic multizonal scaffolds for the reconstruction of zonal articular cartilage in chondral and osteochondral defects. (2024). https://doi.org/10.1016/j.bioactmat.2024.10.001 https://doi.org/10.1016/j.bioactmat.2024.10.001
3. [3] Current hip cartilage regeneration/repair modalities: a scoping review of biologics and surgery. (2020). https://doi.org/10.1007/s00264-020-04789-2 https://doi.org/10.1007/s00264-020-04789-2
4. [4] Nonoperative and Operative Bone and Cartilage Regeneration and Orthopaedic Biologics of the Hip: Orthoregeneration Network (ON) Foundation Hip Review. (2021). https://doi.org/10.1016/j.arthro.2021.08.032 https://doi.org/10.1016/j.arthro.2021.08.032
5. [5] PLGA Conical Nail Fixation for Acetabular Chondrolabral Delamination in Femoroacetabular Impingement Promotes Cartilage and Labrum Regeneration. (2025). https://doi.org/10.1177/03635465241299414 https://doi.org/10.1177/03635465241299414
6. [6] PAO combined with one-step autologous cartilage regeneration for advanced hip disease — case series. (2025). https://doi.org/10.1093/jhps/hnaf069.110 https://doi.org/10.1093/jhps/hnaf069.110